Expert Discusses Bipolar Androgen Therapy Plus PARP Inhibition for Castration-Resistant Prostate Cancer

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

At the 2021 European Society for Medical Oncology Congress, CancerNetwork® spoke with Michael Schweizer, MD, assistant professor in the Division of Medical Oncology at the University of Washington School of Medicine and associate professor of the Clinical Research Division at Fred Hutchinson Cancer Research Center, about his research on the combination regimen of olaparib (Lynparza) plus bipolar androgen therapy (BAT) for patients with castration-resistant prostate cancer (CRPC).

The single-center, phase 2 study (NCT03516812) enrolled 36 patients (median age, 70 years; range, 51-88) with CRPC who received either prior abiraterone acetate (Zytiga) and/or enzalutamide (Xtandi) to receive olaparib at 300 mg orally twice daily plus BAT. Almost half (47%) of patients had a PSA50 response, defined as a 50% or greater decline in their PSA level. At a median follow-up of 22.7 months, the median progression-free survival (PFS) was 12.6 months.

Schweizer said this approach is not ready for the clinic yet, but it holds promise for this group of patients being treated by a medical oncologist.


I don't think this is necessarily going to shift the standard of care right now because it’s a relatively small phase 2 trial. You know, hypothetically, if it turned out that this combination was active, they could prove it in a randomized trial, and it became a standard of care, this would probably still fall predominantly on medical oncology to treat these patients since you're talking about utilizing drugs like PARP inhibitors, which tend to be mostly utilized in the medical oncology field.

In theory, I could see if this really panned out to be a therapy that was effective for an unselected population that perhaps it would start going back towards urologists utilizing it more since it doesn’t require sort of advanced genomic testing. For now, it’s probably not going to necessarily be something that relies heavily on a multidisciplinary approach for utilization since it’s a drug-based treatment.


Schweizer M, Gulati R, Yezefski T, et al. Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 European Society for Medical Oncology Congress. September 16-21, 2021. Abstract 592P

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Expert cardiologist
Expert urologist
Related Content